Ex Vivo News and Research

RSS

Researchers develop system to culture normal and cancerous pancreatic tissue isolated from resection specimens obtained from patients

Pancreatic cancer is a devastating disease with a very poor prognosis.

24 Mar 2009

World-first technique used to repair an injured donor lung

For the first time in the world, transplant surgeons at Toronto General Hospital, University Health Network used a new technique to repair an injured donor lung that was unsuitable for transplant, and then successfully transplanted it into a patient.

21 Dec 2008

$EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients$

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

EntreMed, Inc. has announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients.

10 Dec 2008

New method improves immunotherapy

A study published by Elsevier this month in Clinical Immunology, the official journal of the Clinical Immunology Society (CIS), describes a new method that facilitates the induction of a specific type of immune suppressive cells, called 'regulatory T cells' for therapeutic use.

1 Dec 2008

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

VIA Pharmaceuticals, Inc. has announced the results of two Phase 2 studies of its lead drug, VIA-2291.

10 Nov 2008

VistaGen Therapeutics announces new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells

VistaGen Therapeutics, Inc., a biotechnology company using leading-edge embryonic stem cell (ES Cell) technologies for predictive toxicology and drug discovery, has announced new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells. VistaGen has exclusive rights for commercial use in its ES Cell-based tools platform for drug discovery and development.

16 Jun 2008

New approach to treating vision loss caused by type 1 Usher syndrome

A new approach to treating vision loss caused by type 1 Usher syndrome (USH1), the most common condition affecting both sight and hearing, will be unveiled by a scientist at the annual conference of the European Society of Human Genetics tomorrow (Tuesday 3 June).

2 Jun 2008

Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia

Researchers at the University Hospital of Magdeburg (Germany) have discovered that atrial tachycardia is associated with mitochondrial dysfunction and oxidative stress followed by the activation of the NF-kB signalling pathway with induction of NF-kB target gene expression in atrial tissue.

24 Apr 2008

MaxCyte introduces large scale transfection technology - accelerates cell-based assay development

MaxCyte has announced the introduction of its ITF Inline Transfection System, a validated platform for preparative transfection, based on unique flow electroporation technology.

21 Apr 2008

New device for screening potential new drug compounds

A new device invented by researchers at the University of Virginia could save pharmaceutical companies significant time and money in screening potential new drug compounds.

19 Nov 2007

Nanomedicine opens the way for nerve cell regeneration

The ability to regenerate nerve cells in the body could reduce the effects of trauma and disease in a dramatic way.

22 May 2007

Cancer Research Technology to present discovery updates at BioEurope 2006

Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announce that Phil L'Huillier, the Director of Business Management, will present at the BioEurope 2006 Annual International Partnering Conference.

6 Nov 2006

Immunotherapy for heart failure

World Congress of Cardiology Report - Heart failure (HF) is a complex, progressive clinical syndrome that can result from any structural or functional cardiac disorder, such as coronary artery disease or hypertension (high blood pressure), which impairs the ability of the heart to function properly as a pump.

5 Sep 2006

Reovirus may be able to eliminate cancer cells from autologous stem cell transplants

Medical studies show that a common virus may be able to eliminate cancer cells from autologous stem cell transplants.

21 Feb 2006

Oncolytics Biotech granted new patent

Oncolytics Biotech Inc. has been granted U.S. Patent 6,994,858 entitled "Reovirus Clearance of Ras-Mediated Neoplastic Cells from Mixed Cellular Compositions."

7 Feb 2006

Injection of EU funds for a microdose project

A new EU-funded project kicked off this month which aims to bridge the gap between the laboratory and the clinic. The EU Microdose AMS Partnership Programme (EUMAPP) aims to boost Europe’s expertise in micodosing and its application of AMS, or accelerator mass spectrometry, to developing new candidate drugs for treating diseases the world over.

23 Jan 2006

Pretreating a vein graft with edifoligide prior to coronary bypass graft surgery does not lower the rate of graft failure

Coronary artery bypass graft (CABG) surgery is one of the most common surgical procedures performed in the United States, according to background information in the article. In appropriately selected patients, CABG surgery results in improved survival, relief of angina, and improved quality of life. Despite frequent use of artery grafts, vein grafts remain the most frequently used conduit.

13 Nov 2005

Gene therapy for arthritis is both feasible and safe

Gene therapy for arthritis and other non-terminal, debilitating conditions and diseases is both feasible and safe, report researchers who conducted the world's first such test on the approach in patients with advanced rheumatoid arthritis.

6 Jun 2005

Vaccine developed at Rockefeller University boosts natural killer T cells in patients with cancer

A new vaccine designed at The Rockefeller University boosted a type of fast-responding immune system cell called the natural killer T (NKT) cell in patients with advanced cancer. The study surprised researchers by revealing the ability of these NKT cells to spur other, slower-responding immune cells to go to work.

4 May 2005

Halozyme Therapeutics receives FDA clearance for Cumulase

Halozyme Therapeutics has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Cumulase for the treatment of oocytes to facilitate certain in vitro fertilization (IVF) procedures. The active pharmaceutical ingredient in Cumulase is the first and only recombinant human hyaluronidase approved in the United States for cumulus removal in the IVF process.

20 Apr 2005